Search Results for “Pfizer” – Page 37 – media

Moderna coronavirus vaccine shows ‘promising’ safety and immune response results in published Phase 1 study, but more research is needed

(CNN)A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.
- Source: drugdu
- 457
- July 15, 2020
coronavirus vaccine Covid-19 vaccine
Roche to pay Sarepta $1B upfront for DMD gene therapy rights

Roche is paying more than $1 billion upfront for the ex-U.S. rights to Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy SRP-9001. The deal comes days after Roche advanced its push into gene therapies by closing the takeover of Spark Therapeutics. Sarepta has linked SRP-9001 to microdystrophin expression levels of up to 96% in early clinical tests, leading it to start a 24-patient placebo-controlled trial that is due to deliver data next year. Coupled to a safety profile that so far makes SRP-9001 look a better prospect than rival gene therapies from Pfizer and Solid Biosciences, the efficacy data have put Sarepta at the forefront of efforts to develop a one-shot treatment for DMD. That has attracted the attention of Roche. The Swiss drugmaker is set to pay $750 million in cash and $400 million in equity upfront for the ex-U.S. rights to SRP-9001. Sarepta is also in line to ...
- Source: drugdu
- 265
- December 24, 2019
GW Pharma Plans Epidiolex Launch, Making It Stand Out Among Other Cannabis Products

GW Pharmaceutical’s Epidiolex, the cannabidiol CBD that received a green light from the FDA for management of rare variants of epilepsy, is determined to change physicians’ perspectives about it and make it stand out from the oils available at cannabis stores and hence, recruited around 66 sales executives related to neurology dedicated to persuading 5,000 specialists who treat epilepsy in the U.S. “We’re the leader in this area, we’re science-based, and we believe physicians and patients will desire medicines that have gone through the FDA review process. When a drug is prescribed that’s FDA approved, you know it’s exactly the same every time it’s prescribed and every time it’s taken,” said Stephen Schultz, VP of investor relations at GW. In addition to the approval, GW was also granted with the change of class for Epidiolex from a Schedule I drug to a Schedule V which labels it under drugs that ...
- Source: drugdu
- 1,607
- October 18, 2018
Medical Model Training Products are used as a guide for research, diagnosis, and prognosis

Medical Model Training Products are used as a guide for research, diagnosis, and prognosis. As per the recent report of Markets and Markets Research, it was found that the market rate of Medical Model Training Products Suppliers would reach 2,575.4 Million USD by 2022. By considering the upcoming trend of these products, our drugdu (Ddu) team has collaborated with PRO-Health Product Limited in dealing with the supply of medical model training products. PRO-Health Product Limited is the leading Medical Model Training Products Supplier, headquartered in Guangzhou, China, which was originally established in 2007. This company is specialized in providing high-performance laboratory consumables, medical products, pharmaceutical and medical promotional products, patient education and training products. In 2008, the company received ISO13485 and CE certification. Later it was upgraded to ISO9001 certification as their medical products are US-FDA registered. They are specialized in manufacturing products such as pillbox series, cup ...
- Source: drugdu
- 1,353
- September 18, 2018
Novartis’s Alpelisib Treats Advanced Breast Cancer

Finding the ultimate treatment for breast cancer is still a dream for all the pharma companies worldwide. At present, only hormonal therapy, Pfizer’s Ibrance, Eli Lilly’s Verzenio and Novartis’s Kisqali are available for breast cancer treatment.
- Source: Reuters
- 891
- August 24, 2018
breast cancer Company Insight Novartis
Artios Pharma raises $84 Million to take DDR Programs to Next Level

Artios Pharma, a U.K. based company in Cambridge, has raised $84 million to take DNA damage response (DDR) programs to the next level of clinical proof of concept.
- Source: FierceBiotech
- 1,058
- August 14, 2018
cancer Company Insight DNA
Novo Nordisk Observes Lower 2019 U.S. Prices as Sales Fall

Declining sales of chief drugs of Novo Nordisk in the second quarter saw its shares falling on Wednesday, causing it to lower its prices in the key U.S. market next year.
- Source: Reuters
- 660
- August 10, 2018
Market Views Novo Nordisk pharmaceutical company
HitGen and Merck Collaborates For DNA Library Screening

HitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets.
- Source: FierceBiotech
- 1,003
- August 8, 2018
biotech China Company Insight Merck
Janssen, Bayer Plans to Shut South Korean Plants Seeing a Plunging Demand

Janssen Korea becomes yet another drugmaker to shut its Hyangnam plant in Hwaseong, South Korea, by 2021, stranding an uncounted number of employees.
- Source: FiercePharma
- 684
- August 8, 2018
Company Insight pharmaceutical company South Korea
Johnson & Johnson under Justice Department Scrutiny for Funding Iraqi Terrorism

After the disclosure from AstraZeneca that it’s under Justice Department scrutiny for illegally funding Iraqi terrorism, Roche and Johnson & Johnson revealed similar inquiries from the agency.
- Source: FiercePharma
- 557
- August 6, 2018
Company Insight lawsuit pharmaceutical company

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.